CL2013003056A1 - Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas. - Google Patents
Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.Info
- Publication number
- CL2013003056A1 CL2013003056A1 CL2013003056A CL2013003056A CL2013003056A1 CL 2013003056 A1 CL2013003056 A1 CL 2013003056A1 CL 2013003056 A CL2013003056 A CL 2013003056A CL 2013003056 A CL2013003056 A CL 2013003056A CL 2013003056 A1 CL2013003056 A1 CL 2013003056A1
- Authority
- CL
- Chile
- Prior art keywords
- pyridin
- treatment
- pharmaceutical composition
- schizophrenia
- pyrimidin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P70/00—Climate change mitigation technologies in the production process for final industrial or consumer products
- Y02P70/50—Manufacturing or production processes characterised by the final manufactured product
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
- Y02T10/00—Road transport of goods or passengers
- Y02T10/60—Other road transportation technologies with climate change mitigation effect
- Y02T10/70—Energy storage systems for electromobility, e.g. batteries
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Secondary Cells (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Liquid Crystal Substances (AREA)
Abstract
COMPUESTOS DERIVADOS DE (FENIL O PIRIDIN)-ETINIL-(PIRIDIN O PIRIMIDIN) SUSTITUIDO DE FORMULA I COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE; PROCESO DE PREPARACIÓN DE ESTO: Y SU USO EN EL TRATAMIENTO DE LA ESQUIZOFRENIA O ENFERMEDADES COGNITIVAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11163683 | 2011-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003056A1 true CL2013003056A1 (es) | 2014-07-25 |
Family
ID=46025665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003056A CL2013003056A1 (es) | 2011-04-26 | 2013-10-22 | Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas. |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8957213B2 (es) |
| EP (1) | EP2702051B1 (es) |
| JP (1) | JP5753627B2 (es) |
| KR (1) | KR101554803B1 (es) |
| CN (1) | CN103492373B (es) |
| AR (1) | AR086036A1 (es) |
| AU (1) | AU2012247653B2 (es) |
| BR (1) | BR112013026116A2 (es) |
| CA (1) | CA2829170C (es) |
| CL (1) | CL2013003056A1 (es) |
| CO (1) | CO6801734A2 (es) |
| CR (1) | CR20130475A (es) |
| CY (1) | CY1116391T1 (es) |
| DK (1) | DK2702051T3 (es) |
| EA (1) | EA022019B1 (es) |
| ES (1) | ES2534090T3 (es) |
| HR (1) | HRP20150555T1 (es) |
| HU (1) | HUE025031T2 (es) |
| IL (1) | IL228835A (es) |
| MA (1) | MA35133B1 (es) |
| MX (1) | MX337443B (es) |
| MY (1) | MY163164A (es) |
| PE (1) | PE20141169A1 (es) |
| PH (1) | PH12013501895A1 (es) |
| PL (1) | PL2702051T3 (es) |
| PT (1) | PT2702051E (es) |
| RS (1) | RS53903B1 (es) |
| SG (1) | SG194120A1 (es) |
| SI (1) | SI2702051T1 (es) |
| TW (2) | TWI436993B (es) |
| UA (1) | UA110378C2 (es) |
| WO (1) | WO2012146551A1 (es) |
| ZA (1) | ZA201306586B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501895A1 (en) * | 2011-04-26 | 2013-10-14 | Hoffmann La Roche | Ethynyl derivatives as positive allosteric modulators of the mglur5 |
| UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| EP2875000B1 (en) * | 2012-07-17 | 2016-09-21 | F. Hoffmann-La Roche AG | Arylethynyl derivatives |
| EP2909178B1 (en) * | 2012-10-18 | 2016-10-05 | F. Hoffmann-La Roche AG | Ethynyl derivatives as modulators of mglur5 receptor activity |
| UA116023C2 (uk) * | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
| ES2786673T3 (es) | 2015-06-03 | 2020-10-13 | Hoffmann La Roche | Derivados de etinilo |
| TR201909160T4 (tr) | 2015-07-15 | 2019-07-22 | Hoffmann La Roche | Metabotropik glutamat reseptörü modülatörleri olarak etinil türevleri. |
| US10423423B2 (en) | 2015-09-29 | 2019-09-24 | International Business Machines Corporation | Efficiently managing speculative finish tracking and error handling for load instructions |
| JP6936305B2 (ja) | 2016-07-18 | 2021-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | エチニル誘導体 |
| MA50371A (fr) * | 2017-10-10 | 2021-03-31 | Biogen Inc | Procédé de préparation de dérivés spiro |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| CN101223166B (zh) * | 2004-10-07 | 2011-10-19 | 默沙东公司 | 噻唑基mglur5拮抗剂及其应用方法 |
| WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| AU2007267183B2 (en) | 2006-05-31 | 2011-10-20 | F. Hoffmann-La Roche Ag | Aryl-4-ethynyl-isoxazole derivatives |
| WO2008151184A1 (en) * | 2007-06-03 | 2008-12-11 | Vanderbilt University | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| US8034806B2 (en) * | 2007-11-02 | 2011-10-11 | Vanderbilt University | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same |
| US8541434B2 (en) | 2008-08-20 | 2013-09-24 | Merck Sharp & Dohme Corp. | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| PH12013501895A1 (en) * | 2011-04-26 | 2013-10-14 | Hoffmann La Roche | Ethynyl derivatives as positive allosteric modulators of the mglur5 |
-
2012
- 2012-04-23 PH PH1/2013/501895A patent/PH12013501895A1/en unknown
- 2012-04-23 RS RS20150192A patent/RS53903B1/sr unknown
- 2012-04-23 CA CA2829170A patent/CA2829170C/en not_active Expired - Fee Related
- 2012-04-23 MX MX2013011105A patent/MX337443B/es active IP Right Grant
- 2012-04-23 DK DK12718153T patent/DK2702051T3/en active
- 2012-04-23 HU HUE12718153A patent/HUE025031T2/en unknown
- 2012-04-23 BR BR112013026116A patent/BR112013026116A2/pt not_active IP Right Cessation
- 2012-04-23 WO PCT/EP2012/057335 patent/WO2012146551A1/en not_active Ceased
- 2012-04-23 SI SI201230199T patent/SI2702051T1/sl unknown
- 2012-04-23 US US13/452,973 patent/US8957213B2/en active Active
- 2012-04-23 JP JP2014506826A patent/JP5753627B2/ja not_active Expired - Fee Related
- 2012-04-23 SG SG2013074810A patent/SG194120A1/en unknown
- 2012-04-23 PE PE2013002401A patent/PE20141169A1/es active IP Right Grant
- 2012-04-23 EA EA201391537A patent/EA022019B1/ru not_active IP Right Cessation
- 2012-04-23 HR HRP20150555TT patent/HRP20150555T1/hr unknown
- 2012-04-23 EP EP20120718153 patent/EP2702051B1/en active Active
- 2012-04-23 KR KR1020137031119A patent/KR101554803B1/ko not_active Expired - Fee Related
- 2012-04-23 PL PL12718153T patent/PL2702051T3/pl unknown
- 2012-04-23 PT PT127181535T patent/PT2702051E/pt unknown
- 2012-04-23 AU AU2012247653A patent/AU2012247653B2/en not_active Ceased
- 2012-04-23 CN CN201280019903.3A patent/CN103492373B/zh not_active Expired - Fee Related
- 2012-04-23 UA UAA201313475A patent/UA110378C2/uk unknown
- 2012-04-23 ES ES12718153.5T patent/ES2534090T3/es active Active
- 2012-04-23 MY MYPI2013003846A patent/MY163164A/en unknown
- 2012-04-24 TW TW101114577A patent/TWI436993B/zh not_active IP Right Cessation
- 2012-04-24 TW TW101114538A patent/TW201306355A/zh unknown
- 2012-04-24 AR ARP120101405 patent/AR086036A1/es unknown
-
2013
- 2013-08-29 CO CO13205214A patent/CO6801734A2/es active IP Right Grant
- 2013-09-02 ZA ZA2013/06586A patent/ZA201306586B/en unknown
- 2013-09-23 CR CR20130475A patent/CR20130475A/es unknown
- 2013-10-10 IL IL228835A patent/IL228835A/en active IP Right Grant
- 2013-10-22 CL CL2013003056A patent/CL2013003056A1/es unknown
- 2013-11-22 MA MA36462A patent/MA35133B1/fr unknown
-
2015
- 2015-01-06 US US14/590,530 patent/US9212171B2/en active Active
- 2015-05-20 CY CY20151100452T patent/CY1116391T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003056A1 (es) | Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas. | |
| MX373711B (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| BR112012029647A2 (pt) | novos derivados de pirimidinas | |
| UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
| EA201391313A1 (ru) | C4-монометилтритерпеноидные производные и способы их применения | |
| DOP2014000062A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
| CR20120264A (es) | Compuestos | |
| ECSP14013215A (es) | Compuestos novedosos | |
| ECSP13012448A (es) | Nuevas aminopirazoloquinazolinas. | |
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| CL2013002517A1 (es) | Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer. | |
| CL2014000746A1 (es) | Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer. | |
| NI201400081A (es) | Nuevos derivados de indolizina , su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| CL2011001972A1 (es) | Compuestos derivados de pirimidina fusionada, inhibidores akt; proceso de preparacion de dichos compuestos y compuestos intermediarios; compuestos intermediarios; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende y sus usos en el tratamiento de enfermedades hiperproliferativas. | |
| UY32483A (es) | Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio | |
| CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
| MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
| NI201500096A (es) | Compuesto químicos | |
| CR20150171A (es) | Benzamidas | |
| UY34314A (es) | Derivados de anilina, su preparación y su aplicación terapéutica. | |
| CL2013002971A1 (es) | Compuestos derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina-carboxamida, moduladores mglur5; composición farmacéutica que los comprende; proceso de preparación de ellos; y su uso en el tratamiento de esquizofrenia o enfermedades cognitivas. |